Heparin Market Size By Product (Low Molecular Weight Heparin, Unfractionated Heparin), By Source (Porcine, Bovine), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Artery Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026

Published Date: Oct 2020  |  Report ID: GMI4837  |  Authors: Sumant Ugalmugale, Rupali Swain

Report Format: PDF   |   Pages: 150   |   Base Year: 2019




Summary Table of Contents Industry Coverage Methodology

Industry trends

Heparin Market size surpassed USD 4.1 billion in 2019 and is estimated to grow at 6.6% CAGR between 2020 and 2026. Growing prevalence of chronic disease across the globe will positively influence the market growth.
 

Heparin Market

Get more details on this report - Request Free Sample PDF
 

Heparin is widely used clinically in cardiac surgeries, dialysis, and deep vein thrombosis. For instance, according to the Kidney care report, approximately 3 million individuals are suffering from chronic kidney disease (CKD) in U.S. and Canada. Such high number involves kidney dialysis and blood transfusion procedures that require heparin.
 

Competitors are seeking majorly e-commerce channels and coordinating with government agencies to supply, due to disruptions in offline supply chain and regional & country wise lockdown amid the COVID-19 pandemic. The disruption and nationwide lockdown to curb the spread of coronavirus have severely hampered the supply system. However, market players are focusing on novel product development for blood clot treatment, thereby supplementing the heparin market growth.
 

Major manufacturers of heparin have witnessed decrease in their product sales, mainly due to influx of generic versions. However, with the outbreak of swine fever, the prices of Heparin API will increase in the future, thereby leading to an increase in the product cost, thus significantly up-surging the market.
 

Rise in number of patients suffering from coronary heart disease and myocardial infection

Coronary heart disease and myocardial infraction (MI) is considered as a critical and significant public health issue in the U.S. There has been a noticeable rise in the number of patients suffering from coronary artery disease across the world. For instance, according to the American Heart Association report 2018, nearly 1 in 7 deaths take place in U.S. due to coronary heart disease. The report also stated that, the prevalence of myocardial infection in adult is approximately 7.9 million (3%). This has led to a surge in demand for heparin treatment, including surgical procedures. Such rising cases of chronic illness in both geriatric as well as middle aged people will further augment the industry demand.
 

Side effect associated with heparin may hamper the market growth

Side effects associated with heparin may hinder the growth of global heparin market. Heparin-induced thrombocytopenia programs the body’s immune system to develop antibodies against its own platelets, causing the risk of bleeding. Furthermore, prominent market players are trying to develop product, but side effects may adversely affect its adoption rate.
 

Advantages associated with low molecular weight heparin will drive its adoption

Heparin Market

Get more details on this report - Request Free Sample PDF
 

The low molecular weight heparin segment dominated a market share of over 85% in 2019. Low molecular weight heparin offers advantages such as resistance to inhibit activated platelets and low incidence of heparin-induced thrombocytopenia. Few other factors driving the segment growth include better bioavailability, longer half-life, and lower risk of osteoporosis.
 

Proposal of reintroduction of bovine-sourced heparin by U.S. FDA

The bovine segment valuation was over USD 50.4 million in 2019. Bovine mucosa heparin drug product is currently available and manufactured in South America. However, with the outbreak of swine fever in 2017, there was an imminent threat to the supply of heparin as porcine is the largest source of heparin. This led to the proposal of reintroduction of bovine-sourced heparin to lower the dependency on porcine. Such regulatory initiatives will prove to be conducive to the segment growth.
 

Patient preference for high quality care and ease of availability of medicine in hospital settings

Hospital pharmacy segment accounted for 52.6% heparin market share in 2019. Hospital pharmacy mainly monitors the supply of all medicines used in the hospital. Patients prefer hospitals as they offer high quality care and ease of availability of medicines will further drive the segment revenue. Furthermore, increase in hospital admissions for surgeries and treatments will further stimulate the segment size.
 

Increasing mortality rates of venous thromboembolism

Venous thromboembolism segment held revenue of USD 2.2 billion in 2019. Increasing mortality rates of venous thromboembolism is anticipated to contribute towards the segment expansion. For instance, according to the International Society on Thrombosis and Haemostasis, approximately 10 million cases of VTE are recorded globally every year and around 544,000 VTE related deaths are observed every year in Europe.
 

Increasing prevalence of deep venous thromboembolism and pulmonary embolism in North America

  Heparin Market

Get more details on this report - Request Free Sample PDF
 

North America heparin market size was around USD 698 million in 2019 and is expected to reach USD 1.2 billion by 2026 owing to increasing prevalence of deep venous thromboembolism and pulmonary embolism in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), around 60,000 to 100,000 people are estimated to die due to DVT/PE in the U.S. Also, the report stated that, nearly 5% to 8% of the U.S. population has one of several genetic risk factors including inherited thrombophilia that increases the risk for thrombosis. This has led to increase in product demand, fostering the North American market revenue.
 

Adoption of various business strategies will provide new growth avenues for companies

Notable players operating in the market include Amphastar Pharmaceutical, Sanofi, Hepalink group, Pfizer, Leo Pharma, and Laboratories Farmaceuticos Rovi SA. Geographical expansion, product launch & approval and partnerships are the most commonly adopted business strategies to sustain market competition.
 

The market research report on heparin includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

Market, By Product

  • Low molecular weight heparin
  • Unfractionated heparin

Market, By Source

  • Porcine
  • Bovine

Market, By Application

  • Venous thromboembolism
  • Atrial fibrillation/flutter
  • Coronary artery disease
  • Others

Market, By Distribution Channel

  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Poland
    • Austria
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

 

Frequently Asked Questions (FAQ) :

The global heparin market size may depict 6.6% CAGR through 2026, having attained a revenue of USD 4.1 billion in 2019, due to rising prevalence of chronic diseases worldwide.
The low molecular weight segment accounted for 85% of market share in 2019 and may increase substantially by 2026, as this product has resistance to inhibit activated platelets.
In 2019, hospital pharmacy segment held 52.6% of market share. Since patients prefer hospitals as they deliver high quality care and medicines, the segment will majorly push the industry by 2026.
North America market size was worth USD 698 million in 2019 and may register USD 1.2 billion by 2026, on account of the rising prevalence of pulmonary embolism and deep venous thromboembolism in the region.

Premium Report Details

  • Published Date: Oct 2020
  • Pages: 150
  • Tables: 238
  • Charts / Figures: 18
  • Companies covered: 10
  • Countries covered: 19

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X